Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 20.59 USD 0.49% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

Kiniksa Pharmaceuticals Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kiniksa Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Income from Continuing Operations
-$9.1m
CAGR 3-Years
63%
CAGR 5-Years
45%
CAGR 10-Years
N/A
No Stocks Found

Kiniksa Pharmaceuticals Ltd
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Founded with a vision to tackle some of the most challenging inflammatory and autoimmune diseases, Kiniksa Pharmaceuticals Ltd. emerged as a nimble player in the competitive biotechnology landscape. This company, leveraging the vast potential of advanced scientific knowledge and biotechnological breakthroughs, focuses on developing and commercializing innovative therapies. Its portfolio is strategically designed to address unmet needs in the treatment of debilitating diseases. Central to its operations is a robust pipeline of monoclonal antibodies and cutting-edge biologics that promise new hope for patients. Guided by a commitment to rigorous clinical development and strategic collaborations, Kiniksa seeks to navigate the complexities of regulatory pathways, bringing its specialized therapeutic solutions to global markets. The financial engine of Kiniksa's ambitious journey is fueled by a combination of strategic partnerships, successful licensing agreements, and prudent capital allocation. By forging alliances with larger pharmaceutical firms, the company gains access to invaluable resources and distribution channels while minimizing its financial risks. This collaborative approach not only expedites the development process but also amplifies market reach, ensuring that novel treatments are accessible to the patients who need them. Revenue streams are bolstered through a mix of upfront payments, milestone achievements, and royalties as its therapies progress through stages of clinical trials and, finally, into the hands of healthcare providers. This business model, one that intertwines innovation with strategic alliances, is designed to sustain growth, balance risk, and ultimately fulfill the company's mission of transforming patients’ lives.

KNSA Intrinsic Value
28 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Kiniksa Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
-9.1m USD

Based on the financial report for Sep 30, 2024, Kiniksa Pharmaceuticals Ltd's Income from Continuing Operations amounts to -9.1m USD.

What is Kiniksa Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
45%

Over the last year, the Income from Continuing Operations growth was -35%. The average annual Income from Continuing Operations growth rates for Kiniksa Pharmaceuticals Ltd have been 63% over the past three years , 45% over the past five years .

Back to Top